Therefore, in the present study, using a segmental osteoperiosteal bone defect (0.8 cm, in the middle of the left radius) that remained incompletely healed in all control rabbits for 6 weeks (assessed in 2-week intervals), pentadecapeptide BPC-157 was further studied (either percutaneously given locally [10 g/kg body weight] into the bone defect, or applied intramuscularly [intermittently, at postoperative days 7, 9, 14, and 16 at 10 g/kg body weight] or continuously [once per day, postoperative days 721 at 10 g or 10 ng/kg body weight])
If your symptoms return before your next scheduled dose, that is a conversation for your GP, not a cue to add unrecorded top-ups
K.KellyE
I didnt see anything about this on the report (paid $199)
Biological Research for Nursing, 18(5), 515520